Facebook
X
LinkedIn
ForwardFundamentals of Transplant and Cellular Therapy- Day 2 - CRS/ICANS -Enduring Material - Credit offering period June 16, 2026 - December 31, 2026
Caitlin Brown BSN, RN and Marcia Almiron-Wolbert MSN, RN, OCN
* Scientific basis/Immuno-effector cells
References:
https://nci-media.cancer.gov/pdq/media/images/774647.jpg
https://www.aoncology.com/education-posts/understanding-bispecific-therapies-bite/
Target Audience
Physicians, nurses, pharmacists, and allied health care professionals who practice in hematological-medical units, skilled nursing facilities, home care, hospice, radiation oncology, surgical oncology, and/or cellular transplant.
Learning Objectives
Recognize symptoms of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Demonstrate effective assessment skills, maintain thorough documentation, and provide comprehensive care for patients experiencing CRS and ICANS
Course summary
- 0.50 AMA PRA Category 1 Credit™
- 0.50 NCPD Contact hours
Allegheny Health Network is approved as a provider of nursing continuing professional development by Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Allegheny General Hospital designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 NCPD Contact hours
Allegheny Health Network is approved as a provider of nursing continuing professional development by Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.